Jun. 21 at 7:38 PM
$CMMB
We are waiting for one of two critical updates — nothing else matters at this stage.
1️Regulatory news: clarity from the FDA or other authorities that confirms the path forward for CM‑101. This is the cornerstone that reduces risk and validates the company’s exceptional drug asset.
2️Partnership or acquisition news: financing, strategic collaboration, or a buyout. After more than a year and a half of talks, investors expect a concrete outcome, not silence.
Bottom line: Until management delivers either regulatory clarity or a strategic deal, the stock will remain under pressure. But once one of these catalysts is announced, the narrative flips instantly from uncertainty to opportunity.
